Glucose enhances mesangial cell apoptosis

Tarnjit Khera1, John Martin, Stephen Riley

  • 1Institute of Nephrology, School of Medicine, Cardiff University, Heath Park, Cardiff, Wales, UK.

Insights

High glucose levels in diabetic nephropathy promote mesangial cell apoptosis by increasing sensitivity to TGF-beta1, not by increasing its synthesis. This pathway involves reduced NF-kappaB activation and altered Bcl-2:Bax ratios.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Cell Biology

Background:

  • Diabetic nephropathy is characterized by mesangial cell apoptosis, correlating with albuminuria.
  • Understanding glucose's role in mesangial cell apoptosis is crucial for diabetic kidney disease research.

Purpose of the Study:

  • To elucidate the mechanism by which elevated glucose concentrations modulate mesangial cell apoptosis.
  • To investigate the roles of NF-kappaB, Bcl-2/Bax ratio, and TGF-beta1 in high glucose-induced apoptosis.

Main Methods:

  • Mesangial cells were cultured with varying glucose concentrations (5 mM vs. 25 mM) and subjected to serum deprivation.
  • Apoptosis was assessed using Annexin-V staining and mitochondrial potential disruption.
  • Gene expression (Bax, Bcl-2, NF-kappaB) and protein activation (caspase-3, NF-kappaB) were analyzed via RT-PCR and EMSA.
  • The impact of TGF-beta1 and NF-kappaB inhibition (SN50) was evaluated.

Main Results:

  • High glucose (25 mM) enhanced serum deprivation-induced apoptosis, caspase-3 activation, and decreased the Bcl-2:Bax ratio.
  • High glucose inhibited NF-kappaB activation; SN50 treatment mimicked this, increasing apoptosis and decreasing the Bcl-2:Bax ratio.
  • TGF-beta1 addition mimicked high glucose effects; blocking TGF-beta1 antibody inhibited glucose-mediated apoptosis.
  • High glucose increased mesangial cell sensitivity to TGF-beta1, though de novo TGF-beta1 synthesis was not significantly increased.

Conclusions:

  • Elevated glucose concentrations enhance mesangial cell apoptosis following serum deprivation.
  • This effect is likely mediated by increased cellular sensitivity to endogenous TGF-beta1, coupled with inhibited NF-kappaB activation and altered Bcl-2:Bax ratio.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...